Medical technology company RaySearch Laboratories AB (RaySearch) (STO:RAYB) announced on Friday that Proton Therapy Center Czech (Prague PTC) has selected RayStation as its sole treatment planning system.
The company said this is its first order from Czechia.
This order has a total order value of SEK6,2m and the majority of the revenues will be recognised within the second quarter of 2019.
Prague PTC was established in 2012 and has since then been treating patients with a wide scale of cancer diagnoses such as prostate, lung, breast, head-and-neck and brain, using proton therapy.
RaySearch develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare, the next-generation oncology information system, worldwide.
(EUR1.00=SEK10.75)
AdaptHealth plans to close acquisition of PCS business in December 2019
Quest Diagnostics announces quarterly cash dividend
Moberg Pharma posts profit of SEK32.7m in Q1 2019
RaySearch announces EUR1.5m order for RayStation from SPHIC in Shanghai
Xbrane Biopharma swings to loss in Q3 2019
Sinovac Biotech Ltd posts net income of USD6.3m for Q3 2019
Titan Pharmaceuticals announces Q3 2019 financial results
Veloxis Pharmaceuticals swings to profit in first nine months of 2019
Mesa Labs closes acquisition of Gyros Protein Technologies for cash consideration of USD180m
UnitedHealth Group to pay dividend to holders of record as of 9 December 2019
KORU Medical Systems achieves higher USD0.02 per diluted share for Q3 2019
Jazz Pharmaceuticals reports Q3 2019 financial results
AstraZeneca divests rights to Seroquel and Seroquel XR in Europe and Russia for upfront USD178m